Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 12/20 | 0.62 |
| ▸ | IGF1R | P08069 | 8/20 | 0.58 |
| ▸ | JAK2 | O60674 | 1/20 | 0.56 |
| ▸ | PAK3 | O75914 | 1/20 | 0.51 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.51 |
| ▸ | PAK2 | Q13177 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15217677 | 0.85 | PAK1 (0.70) | NTRK1IGF1RPAK3PAK1PAK2 | |
| SCHEMBL15217662 | 0.85 | PAK1 (0.70) | NTRK1IGF1RPAK3PAK1PAK2 | |
| SCHEMBL15209086 | 0.85 | PAK1 (0.70) | NTRK1IGF1RPAK3PAK1PAK2 | |
| SCHEMBL15217683 | 0.81 | NTRK1 (0.72) | NTRK1IGF1RJAK2PAK3PAK1 | |
| SCHEMBL15208643 | 0.80 | NTRK1 (0.63) | NTRK1IGF1RJAK2PAK3PAK1 | |
| SCHEMBL15209316 | 0.78 | IGF1R (0.44) | NTRK1IGF1RPAK3PAK1PAK2 | |
| SCHEMBL23216996 | 0.77 | NTRK1 (0.83) | NTRK1IGF1RJAK2 | |
| SCHEMBL3342109 | 0.77 | NTRK1 (0.83) | NTRK1IGF1RJAK2 | |
| SCHEMBL15208157 | 0.77 | IGF1R (0.46) | NTRK1IGF1RPAK3PAK1PAK2 | |
| SCHEMBL15209220 | 0.77 | IGF1R (0.46) | NTRK1IGF1RPAK3PAK1PAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637537-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637537-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | PAK1, AKT1, RB1 | NTRK1 2347/4885IGF1R 584/4885JAK2 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.